Ikonisys Announces a Partnership Between Hospitex International and the Pathologists Beyond Borders Association
15 Dezember 2023 - 7:30AM
Business Wire
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through
a unique, fully automated solution for medical analysis
laboratories, today announced the partnership between Hospitex
International, world leader in thin layer cytology and cancer
diagnostics, and the Pathologists Beyond Borders Association (APOF:
Associazione Patologi Oltre Frontiera). This partnership represents
a significant step forward in the fight against cancer and aims to
support the development of early cancer diagnosis in developing
countries alongside a player that has been active in the field of
anatomical pathology for over 20 years.
For several years now, Hospitex International has been working
alongside APOF on various international initiatives. In
continuation of their successful collaboration, Hospitex
International is now intensifying its commitment to enhancing
APOF's capabilities by supporting the association in the
implementation of its international projects.
As part of this partnership, the two entities will share their
technical and scientific expertise in order to design systems and
solutions that are easily deployable and scalable, while being
compatible with the specific characteristics of developing
countries.
Paolo Giovenali, President of APOF, and Francesco Trisolini,
CEO at Hospitex state: "Our mission is to save human lives
through early oncology diagnosis. APOF as a non-profit association
of doctors and Hospitex as a developer and supplier of innovative
diagnostic solutions. We have joined forces to create a new model
that is effective and applicable in countries lacking both medical
skills and anatomical pathology facilities. Much remains to be
done, but the synergy of research & development and medicine
can make real impact on the lives of many people living in the most
disadvantaged countries."
The two entities are already working on the first model, within
the framework of concrete projects, which will see the light of day
in the coming months.
About APOF Associazione Patologi Oltre Frontiera
(Association of Pathologists Without Borders) has been working for
over 20 years to help improve health standards in developing
countries by implementing projects aimed at obtaining (and
maintaining) accurate and timely oncology diagnoses. To achieve
this goal, APOF creates ex novo or reactivated anatomic pathology
departments, equipping them with adequate sanitary equipment,
selecting and training local medical and technical staff, studying
and applying technical and administrative procedures adapted to the
local context, and finally installing telemedicine stations that
enable constant remote assistance of a diagnostic, educational,
organizational and technical nature.
About Hospitex International Hospitex International is
the world leading company for cytology standardized monolayer
preparations. With CYTOfast it has re-invented the cytological
diagnostics. Hospitex offers a full range of integrated solutions
aimed at streamlining diagnostic processes in cytology. The global
shortage of expertise in pathology requires tools and technologies
that enable diagnostic safety, efficiency and capacity building. In
this area, Hospitex is recognized as the precision diagnostics
player in cytology.
For more information: https://www.hospitex.com/en/
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
Disclaimer This press release contains forward-looking
statements about the Company's prospects and development. These
statements are sometimes identified by the use of the future tense,
the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should",
"could", "would" or "will" or, where appropriate, the negative of
these terms or any other similar variants or expressions. This
information is not historical data and should not be construed as a
guarantee that the facts and data set forth will occur. This
information is based on data, assumptions and estimates considered
reasonable by the Company. It is subject to change or modification
due to uncertainties relating to the economic, financial,
competitive and regulatory environment. This information contains
data relating to the Company's intentions, estimates and objectives
concerning, in particular, the market, strategy, growth, results,
financial situation and cash flow of the Company. The
forward-looking information contained in this press release is made
only as of the date of this press release. The Company does not
undertake to update any forward-looking information contained in
this press release, except as required by applicable law or
regulation. The Company operates in a competitive and rapidly
changing environment and therefore cannot anticipate all of the
risks, uncertainties or other factors that may affect its business,
their potential impact on its business or the extent to which the
materialization of any one risk or combination of risks could cause
results to differ materially from those expressed in any
forward-looking information, it being recalled that none of this
forward-looking information constitutes a guarantee of actual
results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231214947979/en/
Hospitex International Marco Testini Investor Relations
marketing@hospitex.com
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024